Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Cash & Equivalents: 2019-2022

Historic Cash & Equivalents for ADC Therapeutics (ADCT) over the last 3 years, with Dec 2022 value amounting to $326.4 million.

  • ADC Therapeutics' Cash & Equivalents rose 81401.60% to $310.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $310.4 million, marking a year-over-year increase of 81401.60%. This contributed to the annual value of $326.4 million for FY2022, which is 30.03% down from last year.
  • As of FY2022, ADC Therapeutics' Cash & Equivalents stood at $326.4 million, which was down 30.03% from $466.5 million recorded in FY2021.
  • In the past 5 years, ADC Therapeutics' Cash & Equivalents registered a high of $466.5 million during FY2021, and its lowest value of $115.6 million during FY2019.
  • For the 2-year period, ADC Therapeutics' Cash & Equivalents averaged around $396.5 million, with its median value being $396.5 million (2021).
  • Data for ADC Therapeutics' Cash & Equivalents shows a maximum YoY crashed of 30.03% (in 2022) over the last 5 years.
  • ADC Therapeutics' Cash & Equivalents (Yearly) stood at $115.6 million in 2019, then reached $466.5 million in 2021, then plummeted by 30.03% to $326.4 million in 2022.